Alentis Therapeutics to Present at the European Respiratory Society (ERS) International Congress Post published:August 29, 2023 Continue ReadingAlentis Therapeutics to Present at the European Respiratory Society (ERS) International Congress
Alentis Therapeutics Receives FDA Fast Track Designation for ALE.C04 for the Treatment of Claudin-1 Positive HNSCC Post published:August 24, 2023 Continue ReadingAlentis Therapeutics Receives FDA Fast Track Designation for ALE.C04 for the Treatment of Claudin-1 Positive HNSCC
Alentis Therapeutics Announces First Patient Dosed in Phase 1b “FEGATO-01” Clinical Trial of ALE.F02 for the Treatment of Liver Fibrosis Post published:July 13, 2023 Continue ReadingAlentis Therapeutics Announces First Patient Dosed in Phase 1b “FEGATO-01” Clinical Trial of ALE.F02 for the Treatment of Liver Fibrosis
Alentis Therapeutics Appoints Luca Santarelli as Chairperson Post published:June 29, 2023 Continue ReadingAlentis Therapeutics Appoints Luca Santarelli as Chairperson
Alentis Therapeutics Appoints Prof. David Jayne and Prof. Josep Tabernero to its Scientific Advisory Board Post published:June 21, 2023 Continue ReadingAlentis Therapeutics Appoints Prof. David Jayne and Prof. Josep Tabernero to its Scientific Advisory Board
Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors Post published:June 14, 2023 Continue ReadingAlentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
ALENTIS THERAPEUTICS TO PARTICIPATE IN THE ASCO ANNUAL MEETING AND BIO INTERNATIONAL CONVENTION Post published:May 31, 2023 Continue ReadingALENTIS THERAPEUTICS TO PARTICIPATE IN THE ASCO ANNUAL MEETING AND BIO INTERNATIONAL CONVENTION
ALENTIS THERAPEUTICS AWARDED CHF 2.4M SWISS ACCELERATOR GRANT BY INNOSUISSE Post published:May 9, 2023 Continue ReadingALENTIS THERAPEUTICS AWARDED CHF 2.4M SWISS ACCELERATOR GRANT BY INNOSUISSE
ALENTIS THERAPEUTICS REPORTS POSITIVE TOPLINE RESULTS FROM PHASE 1 MULTIPLE-ASCENDING DOSE COHORTS STUDY Post published:April 26, 2023 Continue ReadingALENTIS THERAPEUTICS REPORTS POSITIVE TOPLINE RESULTS FROM PHASE 1 MULTIPLE-ASCENDING DOSE COHORTS STUDY
ALENTIS TO PRESENT DATA AT AACR Post published:April 14, 2023 Continue ReadingALENTIS TO PRESENT DATA AT AACR